서브비주얼

Program Schedule

Day 4 Program (March. 8) - IDRIC_Korean Session

Time(KST) Program Speaker
08:30-09:00 Registration
09:00-09:15 Welcoming Remarks (KDCA) Jee, Young-mee
(Commissioner,
Korea Disease Control and Prevetion Agency)
Opening Remarks (KNIH) Park, Hyun-Young
(Director,
the Korea National Institute of Health)
Greeting Speech (KNIID) Jang, Hee-Chang
(Director,
Korea National Institute of Infectious Diseases)
09:15-09:25 [Keynote speech 1]
Development Strategies and Plans for the Therapeutics within 100/200 Days in Preparation for the Novel Infectious Disease Pandemic
Kim, Kyung-Chang
(Division Director,
Korea Disease Control and Prevention Agency, National Institute of Health)
09:25-09:35 [Keynote speech 2]
Development Strategies and Plans for the Vaccines within 100/200 Days in Preparation for the Novel Infectious Disease Pandemic
Lee, Yoo-Kyoung
(Division Director,
Korea Disease Control and Prevention Agency, National Institute of Health)

Session 1. Characteristics of Emerging Infectious Diseases and clinical studies

Chair: Park, Man-Seong(Professor, Korea University)
09:35-09:50 Age-depedent differential pathogenesis of SFTSV infections Choi, Young-Ki
(Director, Korea Virus Research Institute)
09:50-10:05 Deglycosylation of human influenza A virus (H3N2) hemagglutinine increases virulence in mice. Choi, Jang-Hoon
(Research officer, KNIID)
10:05-10:20 Clinical presentation and viral shedding in patients with Mpox in South Korea Kim, Min-kyung
(Professor, National Medical Center)
10:20-10:35 Long COVID Research Project in South Korea : What we've learned about long COVID Lee, Ja-Cob
(Professor, Hallym University)
10:35-10:45 Q&A
10:45-11:00 Break

Session 2. Current status and strategies for the development of therapeutics for Emerging Infectious Diseases

Chair: Kim, Ki-Soon(Professor, Korea University)
11:00-11:15 Platforms & Tools to Enable Rapid Pandemic Response Dimitri Lavillette
(Chief Scientific Officer, Institut Pasteur Korea)
11:15-11:30 Development of SARS-CoV-2 S2 Targeted Vaccines and Therapeutic Antibodies Cho, Eun-Wie
(Principal Researcher, Korea Research Institute of Bioscience and Biotechnology)
11:30-11:45 Lessons from COVID-19 for the development of antiviral drugs Han, Soo-Bong
(Director, Korea Institute of Chemical Technology)
11:45-12:00 Acceleration of drug discovery with AI Kim, Woo-Yeon
(Professor, Korea Advanced Institute of Science and Technology)
12:00-12:10 Q&A
12:10-13:00 Lunch

Session 3. Outstanding Achievements in the Development of Vaccines for Emerging Infectious Diseases

Chair: Seong, Baik-Rin(Professor, Yonsei University)
13:00-13:15 Rapid screening of target antigenic site for vaccine development using Fv-antibody library Pyun, Jae-Chul
(Professor, Yonsei University)
13:15-13:30 HAs-NAu strategy for the development of better influenza Kim, Jin-Il
(Professor, Korea University)
13:30-13:45 SFTS mRNA Vaccine Research and Development Kim, Hyeon Guk
(Research officer, KNIID)
13:45-14:00 Broad Spectrum Vaccine and mAbs for Sarbecoviruses Wang Linfa
Professor,
 DUKE-NUS, Singapore   Executive Director for the Programme for Research in Epidemic Preparedness and Response (PREPARE),
Singapore
14:00-14:10 Q&A
14:10-14:25 Break

Session 4. Current Status and Strategies in the Development of Vaccines for Emerging Infectious Disea

Chair: Hong, Kee-Jong(Professor, Gachon University)
14:25-14:40 Vaccine adjuvant platform Yeom, Jeong-Seon
(CEO, CHA Vaccine Institute)
14:40-14:55 SKY mRNA Platform for Prophylactic Vaccine Development Jinan Shin
(Vice President, SK biosciece)
14:55-15:05 Research and Development Strategy for RSV Vaccine Kim, Seok-Kyu
(Director, U Biologics)
15:05-15:15 Strategy to develop effective multivalent COVID-19 vaccines against emerging variants based on adenovirus vector platform Kang, Chang-Yul
(CEO, CELLID)

Panel Discussion

Chair: Seong, Baik-Rin(Professor, Yonsei University)
15:15-15:55 Q&A and Future Collaboration Prospectsl
* Therapeutics:
- Kim, Kyung-Chang(Division Director, Korea Disease Control and Prevention Agency, National Institute of Health)
- Dimitri Lavillette(Chief Scientific Officer, Institut Pasteur Korea)
- Han, Soo-Bong (Director, Korea Institute of Chemical Technology)
- Kim, Woo-Yeon (Professor, Korea Advanced Institute of Science and Technology)

* Vaccines:
- Lee, Yoo-Kyoung(Division Director, Korea Disease Control and Prevention Agency, National Institute of Health)
- Yeom, Jeong-Seon(CEO, CHA Vaccine Institute)
15:55-16:00 Closing Remarks (KNIID)